FHTX — Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Market
- Employees: 112
- Website: https://foghorntx.com
Latest SEC filings for FHTX
- 3 — 2026-10-05
- SCHEDULE 13G/A — 2026-10-05
- 8-K — 2026-10-01
- 10-Q — 2026-08-06
- 8-K — 2026-08-06
- 8-K — 2026-06-24
- SCHEDULE 13G/A — 2026-05-15
- SCHEDULE 13G/A — 2026-05-14
- 8-K — 2026-05-07
- 10-Q — 2026-05-07
Latest FHTX news
- — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX (globenewswire.com)
- — FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law (gurufocus.com)
- — FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law (businesswire.com)
- — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX (prnewswire.com)
- — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX (globenewswire.com)
- — Foghorn extends losses as TD Cowen cuts on Lilly exit (seekingalpha_market)
- — Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal (benzinga.com)
- — Foghorn plunges as Lilly exits collaboration (seekingalpha_market)
- — Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart (barrons.com)
- — Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities (globenewswire.com)
Educational tool only — not investment advice.